ALTOS Biologics, a subsidiary of Alteogen, specializes in the innovation and commercialization of biosimilars. The company develops human hyaluronidase technology aimed at facilitating global technology transfer. It is actively involved in the clinical development of the Eylea® Biosimilar (ALT-L9) and discussions regarding licensing out.